Literature DB >> 12681357

Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.

Masakazu Sawanobori1, Shuichi Yamaguchi, Maki Hasegawa, Miori Inoue, Kenshi Suzuki, Ryuichi Kamiyama, Katsuiku Hirokawa, Masanobu Kitagawa.   

Abstract

Myelodysplastic syndromes (MDS) are characterized by peripheral blood cytopenias despite hypercellularity of the bone marrow regarded as the result of ineffective hematopoiesis mainly caused by apoptosis. In this study, we examined the role of tumor necrosis factor (TNF)-induced apoptosis in the bone marrow cells of MDS patients. The constitutive expression of mRNA for TNF receptors (TNFR), including TNFRI and TNFRII, and the adapter molecules, such as the TNF receptor-associated death domain protein (TRADD), Fas-associated death domain protein (FADD), receptor interacting protein (RIP) and TNF receptor-associated factor 2 (TRAF-2) were analyzed by reverse transcriptase (RT)-PCR in bone marrow samples from control, MDS and AML cases. In bone marrow cells from refractory anemia (RA) patients, there was a significant increase in TNFRI expression as compared with control subjects. The expression of TNFRII was also up-regulated in RA cases. In contrast, RA with excess of blasts (RAEB), RAEB in transformation (RAEB-T) and AML cases revealed increased expression of TNFRII, whereas the expression of TNFRI was comparable to control subjects. Immunohistochemical staining revealed that the TNFRI, as well as TNFRII of MDS bone marrow was expressed mainly in hematopoietic cells, but not in macrophage-lineage stromal cells at the protein level. An increased constitutive expression of mRNA for TRADD, FADD and RIP and decreased expression of mRNA for TRAF-2 were observed in bone marrow cells from MDS patients, especially from RA patients, as compared with controls, although the differences were not significant. In many of the AML bone marrow samples, strong expression of TRAF-2 mRNA was marked, while expression levels of other proteins were similar to those in control subjects. These data suggested enhanced signaling by the TNFRI-TRADD-FADD pathway and suppressed signaling by the TRAF-2 pathway in RA. Thus, TNF-alpha-induced apoptosis may play a role in ineffective hematopoiesis in "early stage MDS" bone marrow, although the regulatory mechanisms for TNF-alpha-induced signaling would be complicated and not be simply explained only by these pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12681357     DOI: 10.1016/s0145-2126(02)00095-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  25 in total

1.  Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.

Authors:  Bart L Scott; Aravind Ramakrishnan; Mark Fosdal; Barry Storer; Pamela Becker; Steve Petersdorf; H Joachim Deeg
Journal:  Br J Haematol       Date:  2010-03-16       Impact factor: 6.998

Review 2.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

3.  Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.

Authors:  Rebekka K Schneider; Monica Schenone; Monica Ventura Ferreira; Rafael Kramann; Cailin E Joyce; Christina Hartigan; Fabian Beier; Tim H Brümmendorf; Ulrich Germing; Uwe Platzbecker; Guntram Büsche; Ruth Knüchel; Michelle C Chen; Christopher S Waters; Edwin Chen; Lisa P Chu; Carl D Novina; R Coleman Lindsley; Steven A Carr; Benjamin L Ebert
Journal:  Nat Med       Date:  2016-02-15       Impact factor: 53.440

Review 4.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

5.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

Review 6.  Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.

Authors:  Ankur R Parikh; Matthew J Olnes; A John Barrett
Journal:  Semin Hematol       Date:  2012-10       Impact factor: 3.851

7.  Loss of SIMPL compromises TNF-alpha-dependent survival of hematopoietic progenitors.

Authors:  Eric A Benson; Mark G Goebl; Feng-Chun Yang; Reuben Kapur; Jeanette McClintick; Sonal Sanghani; D Wade Clapp; Maureen A Harrington
Journal:  Exp Hematol       Date:  2009-11-23       Impact factor: 3.084

8.  Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis.

Authors:  N A Ansari; G K Katara; V Ramesh; P Salotra
Journal:  Clin Exp Immunol       Date:  2008-12       Impact factor: 4.330

Review 9.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

10.  The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome.

Authors:  Min Kyoung Kim; Jae Lyun Lee; Hee Soon Cho; Sung Hwa Bae; Hun Mo Ryoo; Kyung Hee Lee; Myung Soo Hyun
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.